Drug Profile

AVCN 319302

Alternative Names: AVCN-319302

Latest Information Update: 25 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Avicanna
Developer Avicanna; University of Toronto
Class Antiepileptic drugs; Cannabinoids
Mechanism of Action Cannabinoid receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Epilepsy

Most Recent Events

20 Oct 2022 Avicanna files a PCT application for AVCN 319302
20 Oct 2022 Preclinical trials in Epilepsy in Canada (unspecified route) prior to October 2022
20 Oct 2022 Pharmacodynamics data from preclinical studies in Epilepsy released by Avicanna

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com